CMS Finalizes GLOBE Drug Pricing Model for 2027
The federal government finalized a new drug pricing model on September 30, 2026, aimed at lowering Medicare costs.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you feel the financial burden of prescription drug costs is getting worse for your household?
On September 30, 2026, CMS finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) model to calculate Medicare Part B rebates using international standards. The initiative aims to reduce costs for Medicare beneficiaries when it launches on January 1, 2027.
Why it matters
The model seeks to address high prescription drug costs that have forced many Americans to skip or stop their medications entirely. By implementing international benchmarks, regulators hope to curb rising medical expenses for patients and providers alike.
Medicare Advantage premiums are projected to fall by more than 16% from 2026 to 2027, while average prescription drug premiums within those plans are expected to drop 38%. Currently, 66% of physician practices spend at least 5 hours weekly resolving cost issues.
The players
Centers for Medicare & Medicaid Services
This federal agency is a component of the Department of Health and Human Services and administers the Medicare program and federal healthcare initiatives.
United States Congress
The bicameral legislative branch of the federal government is responsible for creating and amending national healthcare policy.
The details
The GLOBE model calculates rebates under the Medicare Part B Drug Inflation Rebate Program using international pricing data to incentivize lower costs. Complementing this, Congress introduced the Biosimilars Access and Affordability Act in late September 2026 to stabilize product launches.
Timeline
September 30, 2026: CMS officially finalized the GLOBE model.
Late September 2026: Congress introduced companion biosimilar legislation.
January 1, 2027: The GLOBE model officially launches.
2026-2027: Period for the projected decline in Medicare Advantage premiums.
Market Landscape
The GLOBE model builds upon the structure of the Medicare Part B Drug Inflation Rebate Program to adjust how rebates are calculated. This shift signals a broader move toward integrating international pricing benchmarks into the domestic healthcare regulatory landscape.
Medicare beneficiaries may see significant reductions in their 2027 premiums due to these adjusted pricing models. Patients should continue to monitor their annual plan documents for changes to out-of-pocket costs and prescription coverage.
The takeaway
The move to international benchmarking represents a significant shift in how Medicare manages drug costs for millions of Americans. Patients struggling with high medication prices should consult with their providers about the availability of biosimilar alternatives.
Further reading
For more context on current regulatory trends in the medical sector, visit the United States Healthcare section.
More information
Read the full details regarding the CMS Medicare Advantage program news release on the official government website.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you feel the financial burden of prescription drug costs is getting worse for your household?
